<DOC>
	<DOCNO>NCT00435812</DOCNO>
	<brief_summary>The purpose study find new investigational hepatitis B virus vaccine , HEPLISAV™ , safe effective compare Engerix-B® vaccine subject 11-55 year old . The primary hypothesis seroprotective immune response HEPLISAV™ least good Engerix-B® .</brief_summary>
	<brief_title>Safety Efficacy HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine</brief_title>
	<detailed_description>This study evaluate safety efficacy two injection HEPLISAV™ , compare three injection commercially available hepatitis B virus ( HBV ) vaccine , Engerix-B® , subject 11 55 year old . About 1,740 subject include study . Once subject consent , screen , randomize treatment , subject receive total three injection 24-week period , follow-up visit 28 week . Subjects randomize Engerix-B® receive 3 injection active vaccine , subject randomize HEPLISAV™ receive 2 injection active vaccine plus 1 injection placebo . Safety tolerability evaluate occurrence adverse event , periodic laboratory test , vital sign , local/systemic reactogenicity . Comparison : Subjects receive treatment either HEPLISAV™ comparator vaccine , Engerix-B® .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Willing able give write informed consent Is serum negative HBV antibody Women pregnant breastfeed Any previous HBV infection Previous vaccination HBV vaccine ( 1 dos ) Any autoimmune disease Received blood product antibody within 3 month prior study entry Ever receive injection DNA plasmids oligonucleotides Received vaccine within 4 week prior study entry Received investigational medicinal agent within 4 week prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HBV vaccine</keyword>
	<keyword>Hepatitis B vaccine</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>HBV</keyword>
	<keyword>Immunostimulatory sequence ( ISS )</keyword>
</DOC>